作者: Stéphane Renaud , Mickaël Schaeffer , Anne-Claire Voegeli , Michèle Legrain , Eric Guérin
DOI: 10.2217/FON.15.273
关键词:
摘要: Background: Our study aimed to evaluate response rate (RR) brain metastasis radiotherapy (RT), depending on the genomic status of non-small-cell lung cancer. Material & methods: We retrospectively reviewed 1971 cancer files patients with EGFR and KRAS testing focused 157 who had undergone RT for metastasis. Results: A total 16 (10.2%) harbored mutations (mEGFR) 45 (28.7%) (mKRAS). In univariate analysis, RR was significantly higher mEGFR compared wild-type EGFR/KRAS (odds ratio [OR]: 4.96; p = 0.05) or mKRAS (OR: 1.81; 0.03). multivariate G12V G12C associated both poor 0.1; < 0.0001) overall survival 3.41; 0.0001). Conclusion: are than EGFR/RAS mKRAS.